-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
-
2023-507803-76-00
10
2024-09-26
Peripheral T-Cell Lymphoma
-
2023-507353-15-00
5
2024-09-10
idiopathic pulmonary fibrosis (IPF)
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2023-508435-31-00
1
2024-08-09
Advanced Solid Tumors, Advanced Breast Cancer
-
2023-503895-25-00
5
2024-08-01
criticall illness
-
2023-504169-22-02
5
2024-07-31
Severe cardiac inflammation
-
2023-508482-32-00
5
2024-07-22
Neutropenias
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
-
2023-507914-28-00
10
2024-06-19
Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade
-
2023-507677-18-00
9
2024-05-17
Chronic Myeloid Leukemia
-
2022-503142-41-00
5
2024-05-06
Mucopolysaccharidosis type II
-
2023-504374-38-00
5
2024-04-12
Locally advanced cervical cancer
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2024-513019-29-00
5
2024-03-22
Major Depression Disorder
-
2023-506714-43-00
4
2024-03-15
ALK positive Non-Small Cell Lung Cancer
-
2023-505251-43-00
5
2024-02-28
Primary Biliary Cholangitis
-
2023-505511-20-00
9
2024-01-29
B-Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
-
2022-503092-28-00
5
2024-01-08
Relapsed/Refractory Follicular Lymphoma
-
2023-504807-94-00
7
2023-12-26
Breast Cancer; Advanced solid tumors including but not limited to gyne
-
2022-502046-28-00
5
2023-12-22
HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
-
2022-502775-29-01
5
2023-12-14
Early stage Follicular Lymphoma
-
2022-501869-41-00
9
2023-11-14
Acute Lymphoblastic Leukemia, in Relapse
Lymphoblastic Lymphoma (Precu